129S;ICR-Vhl^tm1Bjg/J

Stock number: 003123
Product name: VHL-
Research areas: Cancer Research

Description

These Vhl knock-out mice exhibit embryonic lethality with delays in early embryonic development.

Detailed description

Mice homozygous for the Vhl^tm1Bjg targeted mutation are embryonic lethals. Homozygous mutant embryos show delays in early embryonic development. Development continues to 9.5 days after which mutant embryos undergo necrosis and resorption. On a gross morphological level two structures, the branchial arches and limb buds appear to be more significantly affected.

Development

The mutation was made by a gene targeting vector which contains an insertion of the PGK-neo cassette 12 and 72 nucleotides downstream of the two ATG initiation codons. The VHL protein has been shown to act as a competitive inhibitor of the action of the transcription elongation complex SIII in vitro. It has also been implicated in the negative regulation of VEGF. The effect of the null mutation has not been characterized at the molecular level. The strain originated on a 129Sv/J-ICR F1 hybrid background.

Allele

Symbol: Vhl^tm1Bjg
Name: targeted mutation 1, Brian J Gavin
MGI accession ID: MGI:2658719
Generation method: Targeted
Attributes: Null/Knockout
Marker symbol: Vhl
Marker name: von Hippel-Lindau tumor suppressor
Chromosome: 6
Strain of origin: 129S1/Sv-Oca2⁺ Tyr⁺ Kitl⁺
Molecular note: Molecular details for this gene targeted allele are unpublished and not available.